DE60131973T2 - Regulation der upa gen-expression durch methylierte nukleotide - Google Patents

Regulation der upa gen-expression durch methylierte nukleotide Download PDF

Info

Publication number
DE60131973T2
DE60131973T2 DE60131973T DE60131973T DE60131973T2 DE 60131973 T2 DE60131973 T2 DE 60131973T2 DE 60131973 T DE60131973 T DE 60131973T DE 60131973 T DE60131973 T DE 60131973T DE 60131973 T2 DE60131973 T2 DE 60131973T2
Authority
DE
Germany
Prior art keywords
sequence
complementary
upa
seq
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60131973T
Other languages
German (de)
English (en)
Other versions
DE60131973D1 (de
Inventor
Shafaat A. Westmount RABBANI
Clarke Montreal SLEMON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaip Greenwich Conn Us LLC
Original Assignee
Quebepharma Recherche Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quebepharma Recherche Inc filed Critical Quebepharma Recherche Inc
Publication of DE60131973D1 publication Critical patent/DE60131973D1/de
Application granted granted Critical
Publication of DE60131973T2 publication Critical patent/DE60131973T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE60131973T 2000-07-13 2001-07-13 Regulation der upa gen-expression durch methylierte nukleotide Expired - Lifetime DE60131973T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002312051A CA2312051A1 (en) 2000-07-13 2000-07-13 Methylated nucleotide regulation of gene expression
CA2312051 2000-07-13
PCT/CA2001/001023 WO2002006462A2 (en) 2000-07-13 2001-07-13 Methylated nucleotide regulation of upa gene expression

Publications (2)

Publication Number Publication Date
DE60131973D1 DE60131973D1 (de) 2008-01-31
DE60131973T2 true DE60131973T2 (de) 2008-12-04

Family

ID=4166531

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60131973T Expired - Lifetime DE60131973T2 (de) 2000-07-13 2001-07-13 Regulation der upa gen-expression durch methylierte nukleotide

Country Status (9)

Country Link
US (1) US7316900B2 (enExample)
EP (1) EP1303599B1 (enExample)
JP (1) JP2004504028A (enExample)
AT (1) ATE381616T1 (enExample)
AU (2) AU7620501A (enExample)
CA (1) CA2312051A1 (enExample)
DE (1) DE60131973T2 (enExample)
ES (1) ES2298243T3 (enExample)
WO (1) WO2002006462A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589986A1 (en) * 2004-12-07 2006-06-15 Releaf Security and storage system and method
FR2886946B1 (fr) * 2005-06-09 2007-08-10 Biomerieux Sa Procede pour le diagnoctic/pronostic du cancer du sein
US9023819B2 (en) * 2008-06-09 2015-05-05 National Chung Cheng University Treatment of a disease or a condition associated with aberrant gene hypomethylation by a method involving tailored epigenomic modification
US20100161039A1 (en) 2008-12-23 2010-06-24 Vipul Dave Adhesion promoting temporary mask for coated surfaces
TWI393779B (zh) * 2009-10-16 2013-04-21 Nat Univ Chung Cheng 用於哺乳動物細胞的三元件基因表現報導系統及其應用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5000000A (en) * 1988-08-31 1991-03-19 University Of Florida Ethanol production by Escherichia coli strains co-expressing Zymomonas PDC and ADH genes
US5840497A (en) 1993-06-11 1998-11-24 The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization Method for specific silencing of genes by DNA methylation
US5552390A (en) * 1993-12-09 1996-09-03 The Board Of Regents Of The University Of Nebraska Phosphorothioate inhibitors of metastatic breast cancer
US6017704A (en) * 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5874416A (en) 1997-11-07 1999-02-23 Sheikhnejad; Gholamreza RAS antisense inhibition
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6900016B1 (en) * 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof

Also Published As

Publication number Publication date
CA2312051A1 (en) 2002-01-13
AU2001276205B2 (en) 2006-02-16
DE60131973D1 (de) 2008-01-31
ATE381616T1 (de) 2008-01-15
WO2002006462A2 (en) 2002-01-24
US7316900B2 (en) 2008-01-08
US20040053259A1 (en) 2004-03-18
WO2002006462A3 (en) 2002-10-24
EP1303599B1 (en) 2007-12-19
ES2298243T3 (es) 2008-05-16
JP2004504028A (ja) 2004-02-12
AU7620501A (en) 2002-01-30
EP1303599A2 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
DE69533697T2 (de) ANTISENSE OLIGONUKLEOTIDMODULATION DER raf GENEXPRESSION
DE69620906T2 (de) Antisense-oligonukleotidmodulation der raf-genexpression
DE69432934T2 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
DE69232032T2 (de) Antisense oligonukleotide
US5656612A (en) Antisense oligonucleotide modulation of raf gene expression
DE69028694T2 (de) Verfahren und zubereitungen zur krebsbehandlung mit oligonukleotiden
DE69331467T2 (de) Oligonukleotide modulation von protein kinase c
EP0881914B1 (en) Methoxyethoxy oligonucleotides for modulation of protein kinase c expression
US6358932B1 (en) Antisense oligonucleotide inhibition of raf gene expression
JP2017200952A (ja) 真核細胞におけるエキソンスキッピングの誘導
AU685074B2 (en) Administration of oligonucleotides antisense to dopamine receptor MRNA for diagnosis and treatment of neurological pathologies
US5885970A (en) Antisense oligonucleotides against human protein kinase C
DE60131973T2 (de) Regulation der upa gen-expression durch methylierte nukleotide
DE60025595T2 (de) Verfahren zum Diagnostizieren der Suszeptibilität eines Diabetikers für ein erhöhtes Risiko für die Entwicklung von diabetischer Retinopathie
KR100823120B1 (ko) 전립선암 및 기타 내분비계 암 치료용 안티센스인슐린유사성장인자 결합단백질-2-올리고디옥시뉴클레오티드
US5922686A (en) Oligonucleotide modulation of protein kinase C
AU2001276205A1 (en) Methylated Nucleotide Regulation of UPA Gene Expression
EP1427824B1 (de) Verwendung von molekularbiologisch hergestellten, nicht-viralen wirkstoffen zur behandlung der akne
WO2025088215A1 (en) Methods of treatment of melanocytic disease
AU2023366354A1 (en) Methods of treatment of melanocytic disease
WO2024089274A2 (en) Methods of treatment of melanocytic disease
CA2415723A1 (en) Methylated nucleotide regulation of upa gene expression
KR20200048741A (ko) Ell 발현 촉진 물질을 포함하는 피부 장벽기능 강화용 조성물 및 ell 촉진 물질의 스크리닝 방법
HK1015792B (en) Antisense oligonucleotide modulation of raf gene expression

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: PHARMAIP LLC, GREENWICH, CONN., US